MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Ardian, Inc., a pioneer in catheter-based therapies for hypertension and related conditions, today announced that results from the company’s Symplicity HTN-2 trial will be the subject of a late breaking clinical trial presentation this week at the American Heart Association Scientific Sessions 2010 in Chicago, Ill.
